The role of tumor initiating cells in drug resistance of breast cancer: Implications for future therapeutic approaches

Drug Resistance Updates

Volumn 13, Issue 4-5, 2010, Pages 99-108

  Lacerda, Lara ^a   Pusztai, Lajos ^a   Woodward, Wendy A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Breast cancer; Cancer stem cells (CSCs); Cyclopamine; Early relapse; Late recurrence; Perfosine; Repertaxin; Sulphoraphane; Tumor initiating cell directed therapies; Tumor initiating cells (TICs)

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; CISPLATIN; CURCUMIN; CYCLOPAMINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOFEQUIDAR FUMARATE; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; IS 3295; LAPATINIB; LETROZOLE; METFORMIN; METHOTREXATE; MITOXANTRONE; PACLITAXEL; PERIFOSINE; PIPERINE; PROTEIN INHIBITOR; RAPAMYCIN; SALINOMYCIN; SULFORAPHANE; TRASTUZUMAB; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ARTICLE; BREAST CANCER; CANCER RECURRENCE; CANCER RESISTANCE; CANCER STEM CELL; CLINICAL TRIAL; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION PROFILING; HUMAN; NONHUMAN; PRIORITY JOURNAL; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST; BREAST NEOPLASMS; DISEASE PROGRESSION; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; MICE; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEOPLASTIC STEM CELLS;

EID: 77957961187     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.drup.2010.08.001     Document Type: Article

References (98)

1. Early Breast Cancer Trials Collaborative Group, 2002. Multi-agent chemotherapy for early breast cancer. Cochrane Database Syst. Rev. p. CD000487.
2. Abraham B.K., Fritz P., McClellan M., Hauptvogel P., Athelogou M., Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin. Cancer Res. 2005, 11:1154-1159.
3. Al-Hajj M., Wicha M.S., Benito-Hernandez A., Morrison S.J., Clarke M.F. Prospective identification of tumorigenic breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:3983-3988.
4. Auvinen P., Tammi R., Tammi M., Johansson R., Kosma V.M. Expression of CD44s, CD44v3 and CD44v6 in benign and malignant breast lesions: correlation and colocalization with hyaluronan. Histopathology 2005, 47:420-428.
5. Balic M., Lin H., Young L., Hawes D., Giuliano A., McNamara G., Datar R.H., Cote R.J. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin. Cancer Res. 2006, 12:5615-5621.
6. Bandyopadhyay A., Wang L., Agyin J., et al. Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models. PLoS One 2010, 5:e10365.
7. Berner H.S., Suo Z., Risberg B., et al. Clinicopathological associations of CD44 mRNA and protein expression in primary breast carcinomas. Histopathology 2003, 42:546-554.
8. Berry D.A., Cirrincione C., Henderson I.C., Citron M.L., Budman D.R., Goldstein L.J. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006, 295:1658-1667.
9. Bourguignon L.Y., Spevak C.C., Wong G., Xia W., Gilad E. Hyaluronan-CD44 interaction with protein kinase C(epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the Production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J. Biol. Chem. 2009, 284:26533-26546.
10. Broxterman H.J., Gotink K.J., Verheul H.M. Understanding the causes of multidrug resistance in cancer: a comparison of doxorubicin and sunitinib. Drug Resist. Updat. 2009, 12:114-126.
11. Broxterman H.J., Lankelma J., Hoekman K. Resistance to cytotoxic and anti-angiogenic anticancer agents: similarities and differences. Drug Resist. Updat. 2003, 6:111-127.
12. Callahan R., Raafat A. Notch signaling in mammary gland tumorigenesis. J. Mammary Gland Biol. Neoplasia 2001, 6:23-36.
13. Charafe-Jauffret E., Ginestier C., Iovino F., Wicinski J., Cervera N., Finetti P., et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res. 2009, 69:1302-1313.
14. Citron M.L., Berry D.A., Cirrincione C., Hudis C., Winer E.P., Gradishar W.J., et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J. Clin. Oncol. 2003, 21:1431-1439.
15. Creighton C.J., Li X., Landis M., Dixon J.M., Neumeister V.M., Sjolund A., et al. Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc. Natl. Acad. Sci. U.S.A. 2009, 106:13820-13825.
16. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
17. Desmedt C., Piette F., Loi S., Wang Y., Lallemand F., Haibe-Kains B., et al. Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series. Clin. Cancer Res. 2007, 13:3207-3214.
18. Diaz L.K., Zhou X., Wright E.T., Cristofanilli M., Smith T., Yang Y., et al. CD44 expression is associated with increased survival in node-negative invasive breast carcinoma. Clin. Cancer Res. 2005, 11:3309-3314.
19. Diehn M., Cho R.W., Lobo N.A., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
20. Dontu G., Abdallah W.M., Foley J.M., Jackson K.W., Clarke M.F., Kawamura M.J., Wicha M.S. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev. 2003, 17:1253-1270.
21. Eyler C.E., Rich J.N. Survival of the fittest: cancer stem cells in therapeutic resistance and angiogenesis. J. Clin. Oncol. 2008, 26:2839-2845.
22. Farnie G., Clarke R.B., Spence K., Pinnock N., Brennan K., Anderson N.G., Bundred N.J. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J. Natl. Cancer Inst. 2007, 99:616-627.
23. Fiaschi M., Rozell B., Bergstrom A., Toftgard R. Development of mammary tumors by conditional expression of GLI1. Cancer Res. 2009, 69:4810-4817.
24. Fojo T. Multiple paths to a drug resistance phenotype: mutations, translocations, deletions and amplification of coding genes or promoter regions, epigenetic changes and microRNAs. Drug Resist. Updat. 2007, 10:59-67.
25. Ginestier C., Hur M.H., Charafe-Jauffret E., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
26. Ginestier C., Liu S., Diebel M.E., Korkaya H., Luo M., Brown M., et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J. Clin. Invest. 2010, 120:485-497.
27. Ginestier C., Wicinski J., Cervera N., Monville F., Finetti P., Bertucci F., et al. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle 2009, 8:3297-3302.
28. Grange C., Lanzardo S., Cavallo F., Camussi G., Bussolati B. Sca-1 identifies the tumor-initiating cells in mammary tumors of BALB-neuT transgenic mice. Neoplasia 2008, 10:1433-1443.
29. Gupta P.B., Onder T.T., Jiang G., et al. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659.
30. Han J.S., Crowe D.L. Tumor initiating cancer stem cells from human breast cancer cell lines. Int. J. Oncol. 2009, 34:1449-1453.
31. Harrison H., Farnie G., Howell S.J., Rock R.E., Stylianou S., Brennan K.R., Bundred N.J., Clarke R.B. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res. 2010, 70:709-718.
32. Hermann P.C., Huber S.L., Herrler T., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
33. Hirose H., Ishii H., Mimori K., Ohta D., Ohkuma M., Tsujii H., et al. Notch pathway as candidate therapeutic target in Her2/Neu/ErbB2 receptor-negative breast tumors. Oncol. Rep. 2010, 23:35-43.
34. Hirsch H.A., Iliopoulos D., Tsichlis P.N., Struhl K. Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res. 2009, 69:7507-7511.
35. Hirschmann-Jax C., Foster A.E., Wulf G.G., Nuchtern J.G., Jax T.W., Gobel U., Goodell M.A., Brenner M.K. A distinct " side population" of cells with high drug efflux capacity in human tumor cells. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:14228-14233.
36. Jordan C.T., Guzman M.L., Noble M. Cancer stem cells. N. Engl. J. Med. 2006, 355:1253-1261.
37. Kakarala M., Brenner D.E., Korkaya H., Cheng C., Tazi K., Ginestier C., et al. Targeting breast stem cells with the cancer preventive compounds curcumin and piperine. Breast Cancer Res. Treat. 2010, 122:777-785.
38. Karimi-Busheri F., Rasouli-Nia A., Mackey J.R., Weinfeld M. Senescence evasion by MCF-7 human breast tumor-initiating cells. Breast Cancer Res. 2010, 12:R31.
39. Katayama R., Koike S., Sato S., Sugimoto Y., Tsuruo T., Fujita N. Dofequidar fumarate sensitizes cancer stem-like side population cells to chemotherapeutic drugs by inhibiting ABCG2/BCRP-mediated drug export. Cancer Sci. 2009, 100:2060-2068.
40. Kim C.F., Jackson E.L., Woolfenden A.E., Lawrence S., Babar I., Vogel S., Crowley D., Bronson R.T., Jacks T. Identification of bronchioalveolar stem cells in normal lung and lung cancer. Cell 2005, 121:823-835.
41. Klopp A., Woodward W. Therapeutic strategies to eliminate breast cancer stem cells. Curr. Breast Cancer Rep. 2009, 1:222-228.
42. Korkaya H., Paulson A., Charafe-Jauffret E., Ginestier C., Brown M., Dutcher J., Clouthier S.G., Wicha M.S. Regulation of mammary stem/progenitor cells by PTEN/Akt/beta-catenin signaling. PLoS Biol. 2009, 7:e1000121.
43. Korkaya H., Paulson A., Iovino F., Wicha M.S. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion. Oncogene 2008, 27:6120-6130.
44. Lagadec C., Vlashi E., Della Donna L., Meng Y., Dekmezian C., Kim K., Pajonk F. Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res. 2010, 12:R13.
45. Lee J.H., Jung C., Javadian-Elyaderani P., Schweyer S., Schutte D., Shoukier M., et al. Pathways of proliferation and antiapoptosis driven in breast cancer stem cells by stem cell protein piwil2. Cancer Res. 2010, 70:4569-4579.
46. Lewis M.T., Veltmaat J.M. Next stop, the twilight zone: hedgehog network regulation of mammary gland development. J. Mammary Gland Biol. Neoplasia 2004, 9:165-181.
47. Li H.Z., Yi T.B., Wu Z.Y. Suspension culture combined with chemotherapeutic agents for sorting of breast cancer stem cells. BMC Cancer 2008, 8:135.
48. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 2008, 100:672-679.
49. Li Y., Welm B., Podsypanina K., Huang S., Chamorro M., Zhang X., et al. Evidence that transgenes encoding components of the Wnt signaling pathway preferentially induce mammary cancers from progenitor cells. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:15853-15858.
50. Li Y., Zhang T., Korkaya H., Liu S., Lee H.F., Newman B., Yu Y., et al. Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin. Cancer Res. 2010, 16:2580-2590.
51. Liedtke C., Mazouni C., Hess K.R., Andre F., Tordai A., Mejia J.A., et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. 2008, 26:1275-1281.
52. Lindvall C., Evans N.C., Zylstra C.R., Li Y., Alexander C.M., Williams B.O. The Wnt signaling receptor Lrp5 is required for mammary ductal stem cell activity and Wnt1-induced tumorigenesis. J. Biol. Chem. 2006, 281:35081-35087.
53. Liu B.Y., McDermott S.P., Khwaja S.S., Alexander C.M. The transforming activity of Wnt effectors correlates with their ability to induce the accumulation of mammary progenitor cells. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:4158-4163.
54. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006, 5:67.
55. Liu S., Dontu G., Mantle I.D., Patel S., Ahn N.S., Jackson K.W., Suri P., Wicha M.S. Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells. Cancer Res. 2006, 66:6063-6071.
56. Magnifico A., Albano L., Campaner S., Delia D., Castiglioni F., Gasparini P., et al. Tumor-initiating cells of HER2-positive carcinoma cell lines express the highest oncoprotein levels and are sensitive to trastuzumab. Clin. Cancer Res. 2009, 15:2010-2021.
57. Mani S.A., Guo W., Liao M.J., Eaton E.N., Ayyanan A., Zhou A.Y., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
58. Marangoni E., Lecomte N., Durand L., de Pinieux G., Decaudin D., Chomienne C., Smadja-Joffe F., Poupon M.F. CD44 targeting reduces tumour growth and prevents post-chemotherapy relapse of human breast cancers xenografts. Br. J. Cancer 2009, 100:918-922.
59. Mazzone M., Selfors L.M., Albeck J., Overholtzer M., Sale S., Carroll D.L., et al. Dose-dependent induction of distinct phenotypic responses to Notch pathway activation in mammary epithelial cells. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:5012-5017.
60. Mine T., Matsueda S., Li Y., Tokumitsu H., Gao H., Danes C., Wong K.K., et al. Breast cancer cells expressing stem cell markers CD44+ CD24low are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol. Immunother. 2009, 58:1185-1194.
61. Misra S., Hascall V.C., De Giovanni C., Markwald R.R., Ghatak S. Delivery of CD44 shRNA/nanoparticles within cancer cells: perturbation of hyaluronan/CD44v6 interactions and reduction in adenoma growth in Apc Min/+ MICE. J. Biol. Chem. 2009, 284:12432-12446.
62. Muss H.B., Berry D.L., Cirrincione C., Theodoulou M., Mauer A., Cohen H., et al. Intergroup, Standard chemotherapy (CMF or AC) versus capecitabine in early-stage breast cancer (BC) patients aged 65 and older: results of CALGB/CTSU 49907. J. Clin. Oncol. 2008, 26. (Abstract).
63. Mylona E., Giannopoulou I., Fasomytakis E., Nomikos A., Magkou C., Bakarakos P., Nakopoulou L. The clinicopathologic and prognostic significance of CD44+/CD24(-/low) and CD44-/CD24+ tumor cells in invasive breast carcinomas. Hum. Pathol. 2008, 39:1096-1102.
64. Nakanishi T., Chumsri S., Khakpour N., Brodie A.H., Leyland-Jones B., Hamburger A.W., Ross D.D., Burger A.M. Side-population cells in luminal-type breast cancer have tumour-initiating cell properties, and are regulated by HER2 expression and signalling. Br. J. Cancer 2010, 102:815-826.
65. Neumeister V., Agarwal S., Bordeaux J., Camp R.L., Rimm D.L. In situ identification of putative cancer stem cells by multiplexing ALDH1, CD44, and cytokeratin identifies breast cancer patients with poor prognosis. Am. J. Pathol. 2010, 176:2131-2138.
66. Nowell P.C. The clonal evolution of tumor cell populations. Science 1976, 194:23-28.
67. Nusse R. Wnt signaling and stem cell control. Cell Res. 2008, 18:523-527.
68. Pece S., Tosoni D., Confalonieri S., Mazzarol G., Vecchi M., Ronzoni S., et al. Biological and molecular heterogeneity of breast cancers correlates with their cancer stem cell content. Cell 2010, 140:62-73.
69. Phillips T.M., McBride W.H., Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J. Natl. Cancer Inst. 2006, 98:1777-1785.
70. Pusztai L., Hortobagyi G.N. High-dose chemotherapy: how resistant is breast cancer?. Drug Resist. Updat. 1998, 1:62-72.
71. Reim F., Dombrowski Y., Ritter C., Buttmann M., Hausler S., Ossadnik M., et al. Immunoselection of breast and ovarian cancer cells with trastuzumab and natural killer cells: selective escape of CD44high/CD24low/HER2low breast cancer stem cells. Cancer Res. 2009, 69:8058-8066.
72. Saito K., Inagaki S., Mituyama T., et al. A regulatory circuit for piwi by the large Maf gene traffic jam in Drosophila. Nature 2009, 461:1296-1299.
73. Sarkar F.H., Li Y., Wang Z., Kong D., Ali S. Implication of microRNAs in drug resistance for designing novel cancer therapy. Drug Resist. Updat. 2010, 13:57-66.
74. Shafee N., Smith C.R., Wei S., Kim Y., Mills G.B., Hortobagyi G.N., Stanbridge E.J., Lee E.Y. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res. 2008, 68:3243-3250.
75. Shipitsin M., Campbell L.L., Argani P., Weremowicz S., Bloushtain-Qimron N., Yao J., et al. Molecular definition of breast tumor heterogeneity. Cancer Cell 2007, 11:259-273.
76. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
77. Sjolund J., Manetopoulos C., Stockhausen M.T., Axelson H. The Notch pathway in cancer: differentiation gone awry. Eur. J. Cancer 2005, 41:2620-2629.
78. Tanaka H., Nakamura M., Kameda C., Kubo M., Sato N., Kuroki S., Tanaka M., Katano M. The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-/low subpopulation and the side population of breast cancer cells. Anticancer Res. 2009, 29:2147-2157.
79. Tanei T., Morimoto K., Shimazu K., Kim S.J., Tanji Y., Taguchi T., et al. Association of breast cancer stem cells identified by aldehyde dehydrogenase 1 expression with resistance to sequential Paclitaxel and epirubicin-based chemotherapy for breast cancers. Clin. Cancer Res. 2009, 15:4234-4241.
80. Tepera S.B., McCrea P.D., Rosen J.M. A beta-catenin survival signal is required for normal lobular development in the mammary gland. J. Cell Sci. 2003, 116:1137-1149.
81. Theodoropoulos P.A., Polioudaki H., Agelaki S., Kallergi G., Saridaki Z., Mavroudis D., Georgoulias V. Circulating tumor cells with a putative stem cell phenotype in peripheral blood of patients with breast cancer. Cancer Lett. 2010, 288:99-106.
82. To K., Fotovati A., Reipas K.M., Law J.H., Hu K., Wang J., et al. Y-box binding protein-1 induces the expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res. 2010, 70:2840-2851.
83. Todaro M., Alea M.P., Di Stefano A.B., Cammareri P., Vermeulen L., Iovino F. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 2007, 1:389-402.
84. Toole B.P., Slomiany M.G. Hyaluronan, CD44 and Emmprin: partners in cancer cell chemoresistance. Drug Resist. Updat. 2008, 11:110-121.
85. Tremblay, M.R., Nesler, M., Weatherhead, R., Castro, A.C., 2009. Recent patents for Hedgehog pathway inhibitors for the treatment of malignancy, Expert Opin. Ther. Pat. 19, 1039-1056.
86. Uhr J.W., Scheuermann R.H., Street N.E., Vitetta E.S. Cancer dormancy: opportunities for new therapeutic approaches. Nat. Med. 1997, 3:505-509.
87. Untch M., Möbus V., Kuhn W., Konecny G.E. Intensive dose-dense compared with conventionally scheduled preoperative chemotherapy for high-risk primary breast cancer. J. Clin. Oncol. 2009, 27:2938-2945.
88. Vazquez-Martin A., Oliveras-Ferraros C., Barco S.D., Menendez J.A. The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells. Breast Cancer Res. Treat. 2010, 10.1007/s10549-010-0924-x.
89. Venturini M., Del Mastro M.L., Aitini E., Buzzi P. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial. J. Natl. Cancer Inst. 2005, 97:1724-1733.
90. Vlashi E., Kim K., Lagadec C., Donna L.D., McDonald J.T., Eghbali M., et al. In vivo imaging, tracking, and targeting of cancer stem cells. J. Natl. Cancer Inst. 2009, 101:350-359.
91. Wang J., Wakeman T.P., Lathia J.D., et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 2009, 28:17-28.
92. Wicha M.S., Liu S., Dontu G. Cancer stem cells: an old idea - a paradigm shift. Cancer Res. 2006, 66:1883-1890.
93. Woodward W.A., Chen M.S., Behbod F., Alfaro M.P., Buchholz T.A., Rosen J.M. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:618-623.
94. Wu Q., Ma Q., Shehadeh L.A., Wilson A., Xia L., Yu H., Webster K.A. Expression of the Argonaute protein PiwiL2 and piRNAs in adult mouse mesenchymal stem cells. Biochem. Biophys. Res. Commun. 2010, 396:915-920.
95. Yu F., Yao H., Zhu P., Zhang X., Pan Q., Gong C., et al. Let-7 regulates self-renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
96. Zhang M., Atkinson R.J., Rosen J.M. Selective targeting of radiation-resistant tumor-initiating cells. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:3522-3527.
97. Zhou J., Wulfkuhle J., Zhang H., Gu P., Yang Y., Deng J., et al. Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:16158-16563.
98. Zielske S.P., Spalding A.C., Lawrence T.S. Loss of tumor-initiating cell activity in cyclophosphamide-treated breast xenografts. Transl. Oncol. 2010, 3:149-152.